Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease

Are different fixed-dose long-acting muscarinic antagonist (LAMA)–long-acting β-agonists (LABA) associated with differential clinical outcomes among patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice?In this active comparator new-user cohort study of 55 817 matched pairs, once-daily umeclidinium-vilanterol dry powder inhalers were associated with a 14% lower hazard of moderate or severe COPD exacerbations than twice-daily glycopyrrolate-formoterol metered-dose inhalers and a 3% lower hazard than once-daily tiotropium-olodaterol soft mist inhalers.Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers among new users of LAMA-LABA therapy.

Corresponding Author: William B. Feldman, MD, DPhil, MPH, Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy, Department of Medicine, University of California, Los Angeles, 200 Medical Plaza, Suite 365, Los Angeles, CA 90095 (wfeldman@mednet.UCLA.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.